Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy.
Surg Endosc. 2023 Mar;37(3):1742-1748. doi: 10.1007/s00464-022-09696-8. Epub 2022 Oct 10.
The end-stage achalasia is a difficult condition to treat, for the esophageal diameter and conformation of the gullet, that may progress to a sigmoid shape. The aim of this study was to examine the outcome of Laparoscopic Heller-Dor in patients with end-stage achalasia, comparing them with patients who had mega-esophagus without a sigmoid shape.
From 1992 to 2020, patients with a diagnosis of sigmoid esophagus, or radiological stage IV achalasia (the SE group), and patients with a straight esophagus larger than 6 cm in diameter, or radiological stage III achalasia (the NSE group), were all treated with LHD. The two groups were compared in terms of patients' symptoms, based on the Eckardt score, and on barium swallow, endoscopy and manometry performed before and after the treatment. The failure of the treatment was defined as an Eckardt score > 3, or the need for further treatment.
The study involved 164 patients: 73 in the SE group and 91 in the NSE group. No intra- or postoperative mortality was recorded. The median follow-up was 51 months (IQR 25-107). The outcome was satisfactory in 71.2% of patients in the SE group, and in 89% of those in the NSE group (p = 0.005).
SE is certainly the worst condition of the disease and the final outcome of LHD, in term of symptom control, is inferior compared to NSE. Despite this, almost 3/4 of the SE patients experienced a significant relieve in symptoms after LHD, which may therefore still be the first surgical option to offer to these patients, before considering esophagectomy.
晚期贲门失弛缓症是一种难以治疗的疾病,食管直径和食管形态可能会进展为乙状结肠形状。本研究旨在检查腹腔镜 Heller-Dor 治疗晚期贲门失弛缓症患者的结果,并与无乙状结肠形状的巨食管患者进行比较。
1992 年至 2020 年,所有诊断为乙状结肠或放射学 IV 期贲门失弛缓症(SE 组)的患者,以及食管直径大于 6cm 且为直形的患者,或放射学 III 期贲门失弛缓症(NSE 组)均采用 LHD 治疗。根据 Eckardt 评分比较两组患者的症状,比较治疗前后钡餐、内镜和测压检查结果。将治疗失败定义为 Eckardt 评分>3 或需要进一步治疗。
研究共纳入 164 例患者:SE 组 73 例,NSE 组 91 例。无术中或术后死亡病例。中位随访时间为 51 个月(IQR 25-107)。SE 组中 71.2%的患者治疗效果满意,NSE 组中 89%的患者治疗效果满意(p=0.005)。
SE 肯定是疾病的最差情况,LHD 的最终结果在症状控制方面不如 NSE。尽管如此,近 3/4 的 SE 患者在 LHD 后症状明显缓解,因此在考虑食管切除术之前,LHD 仍然是这些患者的首选手术治疗方法。